keyword
MENU ▼
Read by QxMD icon Read
search

double depression

keyword
https://www.readbyqxmd.com/read/28104409/gigantol-from-dendrobium-chrysotoxum-lindl-binds-and-inhibits-aldose-reductase-gene-to-exert-its-anti-cataract-activity-an-in-vitro-mechanistic-study
#1
Jie Wu, Xue Li, Wencheng Wan, Qiaohong Yang, Weifeng Ma, Dan Chen, Jiangmiao Hu, C-Y Oliver Chen, Xiaoyong Wei
ETHNOPHARMACOLOGICAL RELEVANCE: Dendrobium. chrysotoxum Lindl is a commonly used species of medicinal Dendrobium which belongs to the family of Orchidaceae, locally known as "Shihu" or "Huangcao". D. chrysotoxum Lindl is widely known for medicinal values in traditional Chinese medicine as it possesses anti-inflammatory, anti-hyperglycemic induction, antitumor and antioxidant properties. STUDY AIM: To characterize the interaction between gigantol extracted from D...
January 16, 2017: Journal of Ethnopharmacology
https://www.readbyqxmd.com/read/28104188/maternal-multiple-micronutrient-supplementation-and-other-biomedical-and-socioenvironmental-influences-on-children-s-cognition-at-age-9-12-years-in-indonesia-follow-up-of-the-summit-randomised-trial
#2
Elizabeth L Prado, Susy K Sebayang, Mandri Apriatni, Siti R Adawiyah, Nina Hidayati, Ayuniarti Islamiyah, Sudirman Siddiq, Benyamin Harefa, Jarrad Lum, Katherine J Alcock, Michael T Ullman, Husni Muadz, Anuraj H Shankar
BACKGROUND: Brain and cognitive development during the first 1000 days from conception are affected by multiple biomedical and socioenvironmental determinants including nutrition, health, nurturing, and stimulation. An improved understanding of the long-term influence of these factors is needed to prioritise public health investments to optimise human development. METHODS: We did a follow-up study of the Supplementation with Multiple Micronutrients Intervention Trial (SUMMIT), a double-blind, cluster-randomised trial of maternal supplementation with multiple micronutrients (MMN) or iron and folic acid (IFA) in Indonesia...
February 2017: Lancet Global Health
https://www.readbyqxmd.com/read/28103841/a-two-site-two-arm-34-week-double-blind-parallel-group-randomized-controlled-trial-of-reduced-nicotine-cigarettes-in-smokers-with-mood-and-or-anxiety-disorders-trial-design-and-protocol
#3
Sophia I Allen, Jonathan Foulds, Gladys N Pachas, Susan Veldheer, Corinne Cather, Nour Azzouz, Shari Hrabovsky, Ahmad Hameed, Jessica Yingst, Erin Hammett, Jennifer Modesto, Nicolle M Krebs, Junjia Zhu, Jason Liao, Joshua E Muscat, John Richie, A Eden Evins
BACKGROUND: The U.S. Food and Drug Administration can set standards for cigarettes that could include reducing their nicotine content. Such a standard should improve public health without causing unintended serious consequences for sub-populations. This study evaluates the effect of progressive nicotine reduction in cigarettes on smoking behavior, toxicant exposure, and psychiatric symptoms in smokers with comorbid mood and/or anxiety disorders using a two-site, two-arm, double-blind, parallel group, randomized controlled trial (RCT) in four phases over 34 weeks...
January 19, 2017: BMC Public Health
https://www.readbyqxmd.com/read/28103148/double-whammy-adverse-childhood-events-and-pain-reflect-symptomology-and-quality-of-life-in-women-in-substance-abuse-treatment
#4
Cheryl Zlotnick, Maayan Lawental, Dorit Pud
BACKGROUND: This study examined the profiles of symptoms and health-related quality of life (QOL) of women in substance abuse treatment, comparing those with higher versus lower histories of adverse childhood events (ACE), and those with versus without current pain. METHODS: Adult women in outpatient substance abuse treatment (n = 30) completed questionnaires (cross-sectional study) on topics including drug use, adverse childhood events (ACE), QOL, functional ability, current pain, and depression...
January 19, 2017: Social Work in Health Care
https://www.readbyqxmd.com/read/28100425/safety-and-efficacy-of-adjunctive-second-generation-antidepressant-therapy-with-a-mood-stabiliser-or-an-atypical-antipsychotic-in-acute-bipolar-depression-a-systematic-review-and-meta-analysis-of-randomised-placebo-controlled-trials
#5
Alexander McGirr, Paul A Vöhringer, S Nassir Ghaemi, Raymond W Lam, Lakshmi N Yatham
BACKGROUND: Although mania and hypomania define bipolar disorder, depressive episodes are more common and impairing, with few proven treatments. Adjunctive therapy with second-generation antidepressants is widely used to treat acute bipolar depression, but their efficacy and safety remain controversial. METHODS: In this systematic review and meta-analysis, we searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov from inception to Jan 31, 2016, for randomised, double-blind, placebo-controlled trials of second-generation antidepressants adjunctive to a mood stabiliser or an antipsychotic in patients with acute bipolar depression...
December 2016: Lancet Psychiatry
https://www.readbyqxmd.com/read/28098923/-ssris-and-depressive-symptoms-in-schizophrenia-a-systematic-review
#6
H G van Dijk, E A Dapper, C H Vinkers
Patients with schizophrenia frequently have depressive symptoms. Current guidelines do not provide specific recommendations regarding the treatment of these symptoms, nor do they mention the role that selective serotonin reuptake inhibitors (ssris) can play in the treatment.<br/> AIM: To investigate whether ssris are more effective than placebo in treating depressive symptoms in patients with schizophrenia.<br/> METHOD: We searched the literature systematically using PubMed, embase, Cochrane Library and Psycinfo...
2017: Tijdschrift Voor Psychiatrie
https://www.readbyqxmd.com/read/28091532/development-of-the-neuroimmune-modulator-ibudilast-for-the-treatment-of-alcoholism-a-randomized-placebo-controlled-human-laboratory-trial
#7
Lara A Ray, Spencer Bujarski, Steve Shoptaw, Daniel Jo Roche, Keith Heinzerling, Karen Miotto
Current directions in medication development for alcohol use disorder (AUD) emphasize the need to identify novel molecular targets and efficiently screen new compounds aimed at those targets. Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterases -4 and -10 and macrophage migration inhibitory factor and was recently found to reduce alcohol intake in rats by approximately 50%. To advance medications development for AUD, the present study consists of a randomized, crossover, double-blind, placebo-controlled laboratory study of IBUD in non-treatment seeking individuals with current (ie, past month) mild-to-severe AUD...
January 16, 2017: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28086851/efficacy-of-intermittent-theta-burst-stimulation-itbs-and-10-hz-high-frequency-repetitive-transcranial-magnetic-stimulation-rtms-in-treatment-resistant-unipolar-depression-study-protocol-for-a-randomised-controlled-trial
#8
Samuel Bulteau, Veronique Sébille, Guillemette Fayet, Veronique Thomas-Ollivier, Thibault Deschamps, Annabelle Bonnin-Rivalland, Edouard Laforgue, Anne Pichot, Pierre Valrivière, Elisabeth Auffray-Calvier, June Fortin, Yann Péréon, Jean-Marie Vanelle, Anne Sauvaget
BACKGROUND: The treatment of depression remains a challenge since at least 40% of patients do not respond to initial antidepressant therapy and 20% present chronic symptoms (more than 2 years despite standard treatment administered correctly). Repetitive transcranial magnetic stimulation (rTMS) is an effective adjuvant therapy but still not ideal. Intermittent Theta Burst Stimulation (iTBS), which has only been used recently in clinical practice, could have a faster and more intense effect compared to conventional protocols, including 10-Hz high-frequency rTMS (HF-rTMS)...
January 13, 2017: Trials
https://www.readbyqxmd.com/read/28079675/recent-advances-in-the-management-of-neuropsychiatric-symptoms-in-dementia
#9
Orestes V Forlenza, Júlia Cunha Loureiro, Marcos Vasconcelos Pais, Florindo Stella
PURPOSE OF REVIEW: The present article addresses intriguing questions related to the clinical intervention in distinct neuropsychiatric syndromes of patients with dementia. RECENT FINDINGS: We reviewed 154 articles published between 2015 and 2016 targeting psychopharmacological and nonpharmacological interventions, and safety-tolerability concerns. We selected 115 articles addressing the purpose of this study. Of these, 33 were chosen because they were dedicated to subtopics: agitation (42), depression (33), apathy (18), sleep disorders/anxiety (8), and psychosis (4)...
January 12, 2017: Current Opinion in Psychiatry
https://www.readbyqxmd.com/read/28072765/phase-ii-study-of-the-pi3k-inhibitor-bkm120-in-patients-with-advanced-or-recurrent-endometrial-carcinoma-a-stratified-type-i-type-ii-study-from-the-gineco-group
#10
P-E Heudel, M Fabbro, C Roemer-Becuwe, M C Kaminsky, A Arnaud, F Joly, S Roche-Forestier, J Meunier, C Foa, B You, F Priou, Y Tazi, A Floquet, F Selle, D Berton-Rigaud, A Lesoin, E Kalbacher, A Lortholary, L Favier, I Treilleux, I Ray-Coquard
: Backround:Patients with metastatic endometrial carcinoma have a poor prognosis and PIK3CA mutations and amplifications are common in these cancers. This study evaluated the efficacy and safety of the pure PI3K inhibitor BKM120 in advanced or recurrent endometrial carcinoma. METHODS: This phase II, multicentre, single-arm, double strata (histological low grade (LG) or high grade (HG)) open-label study enrolled patients with histologically confirmed advanced or recurrent endometrial carcinoma who had received not more than one prior chemotherapy regimen...
January 10, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28069279/masitinib-for-treatment-of-severely-symptomatic-indolent-systemic-mastocytosis-a-randomised-placebo-controlled-phase-3-study
#11
Olivier Lortholary, Marie Olivia Chandesris, Cristina Bulai Livideanu, Carle Paul, Gérard Guillet, Ewa Jassem, Marek Niedoszytko, Stéphane Barete, Srdan Verstovsek, Clive Grattan, Gandhi Damaj, Danielle Canioni, Sylvie Fraitag, Ludovic Lhermitte, Sophie Georgin Lavialle, Laurent Frenzel, Lawrence B Afrin, Katia Hanssens, Julie Agopian, Raphael Gaillard, Jean-Pierre Kinet, Christian Auclair, Colin Mansfield, Alain Moussy, Patrice Dubreuil, Olivier Hermine
BACKGROUND: Indolent systemic mastocytosis, including the subvariant of smouldering systemic mastocytosis, is a lifelong condition associated with reduced quality of life. Masitinib inhibits KIT and LYN kinases that are involved in indolent systemic mastocytosis pathogenesis. We aimed to assess safety and efficacy of masitinib versus placebo in severely symptomatic patients who were unresponsive to optimal symptomatic treatments. METHODS: In this randomised, double-blind, placebo-controlled, phase 3 study, we enrolled adults (aged 18-75 years) with indolent or smouldering systemic mastocytosis, according to WHO classification or documented mastocytosis based on histological criteria, at 50 centres in 15 countries...
January 6, 2017: Lancet
https://www.readbyqxmd.com/read/28068987/effects-of-acetyl-dl-leucine-on-cerebellar-ataxia-alcat-trial-study-protocol-for-a-multicenter-multinational-randomized-double-blind-placebo-controlled-crossover-phase-iii-trial
#12
Katharina Feil, Christine Adrion, Julian Teufel, Sylvia Bösch, Jens Claassen, Ilaria Giordano, Holger Hengel, Heike Jacobi, Thomas Klockgether, Thomas Klopstock, Wolfgang Nachbauer, Ludger Schöls, Claudia Stendel, Ellen Uslar, Bart van de Warrenburg, Ingrid Berger, Ivonne Naumann, Otmar Bayer, Hans-Helge Müller, Ulrich Mansmann, Michael Strupp
BACKGROUND: Cerebellar ataxia (CA) is a frequent and often disabling condition that impairs motor functioning and impacts on quality of life (QoL). No medication has yet been proven effective for the symptomatic or even causative treatment of hereditary or non-hereditary, non-acquired CA. So far, the only treatment recommendation is physiotherapy. Therefore, new therapeutic options are needed. Based on three observational studies, the primary objective of the acetyl-DL-leucine on ataxia (ALCAT) trial is to examine the efficacy and tolerability of a symptomatic therapy with acetyl-DL-leucine compared to placebo on motor function measured by the Scale for the Assessment and Rating of Ataxia (SARA) in patients with CA...
January 10, 2017: BMC Neurology
https://www.readbyqxmd.com/read/28068788/a-double-blind-randomized-placebo-controlled-trial-of-lactobacillus-helveticus-and-bifidobacterium-longum-for-the-symptoms-of-depression
#13
Amy R Romijn, Julia J Rucklidge, Roeline G Kuijer, Chris Frampton
OBJECTIVES: This trial investigated whether probiotics improved mood, stress and anxiety in a sample selected for low mood. We also tested whether the presence or severity of irritable bowel syndrome symptoms, and levels of proinflammatory cytokines, brain-derived neurotrophic factor and other blood markers, would predict or impact treatment response. METHOD: Seventy-nine participants (10 dropouts) not currently taking psychotropic medications with at least moderate scores on self-report mood measures were randomly allocated to receive either a probiotic preparation (containing Lactobacillus helveticus and Bifidobacterium longum) or a matched placebo, in a double-blind trial for 8 weeks...
January 1, 2017: Australian and New Zealand Journal of Psychiatry
https://www.readbyqxmd.com/read/28068620/temporal-trends-in-antidepressant-prescribing-to-children-in-uk-primary-care-2000-2015
#14
Jane Sarginson, Roger T Webb, S Jill Stocks, Aneez Esmail, Shruti Garg, Darren M Ashcroft
BACKGROUND: The prevalence of antidepressant prescribing in children and adolescents increased steadily in the United States and parts of Europe between 2005 and 2012 despite regulatory safety warnings. Little is known about the characteristics of those being prescribed antidepressants for the first time. METHODS: A longitudinal study of antidepressant prescribing in 3-17 year olds was carried out using data from the UK Clinical Practice Research Datalink (CPRD) between 2000 and 2015...
January 2, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28068615/effects-of-levomilnacipran-er-on-noradrenergic-symptoms-anxiety-symptoms-and-functional-impairment-in-adults-with-major-depressive-disorder-post-hoc-analysis-of-5-clinical-trials
#15
Pierre Blier, Carl Gommoll, Changzheng Chen, Kenneth Kramer
OBJECTIVE: To evaluate the effects of levomilnacipran extended-release (LVM-ER; 40-120mg/day) on noradrenergic (NA) and anxiety-related symptoms in adults with major depressive disorder (MDD) and explore the relationship between these symptoms and functional impairment. METHODS: Data were pooled from 5 randomized, double-blind, placebo-controlled trials (N=2598). Anxiety and NA Cluster scores were developed by adding selected item scores from the Montgomery-Åsberg Depression Rating Scale (MADRS) and 17-item Hamilton Depression Rating Scale (HAMD17)...
November 15, 2016: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28068613/behavioral-activation-treatment-for-major-depression-a-randomized-trial-of-the-efficacy-of-augmentation-with-cognitive-control-training
#16
Samantha J Moshier, Michael W Otto
BACKGROUND: Major depressive disorder (MDD) is associated with hypoactivation of the dorsolateral prefrontal cortex, a brain region involved in emotion regulation and basic cognitive control processes. Recent studies have indicated that computerized interventions designed to activate this region may reduce depressive and ruminative symptoms. In this double-blind randomized controlled trial, we tested whether one such program, called Cognitive Control Training (CCT), enhanced treatment outcomes when used in adjunct to brief behavior therapy for MDD...
January 3, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28068463/long-term-acute-phase-treatment-with-antidepressants-8-weeks-and-beyond-a-systematic-review-and-meta-analysis-of-randomized-placebo-controlled-trials
#17
Jonathan Henssler, Mona Kurschus, Jeremy Franklin, Tom Bschor, Christopher Baethge
OBJECTIVE: In clinical practice, acute antidepressant treatment is often applied for several months until remission is achieved. However, data on treatment outcomes beyond 8 weeks are sparse and no systematic review exists to date. This study aims at assessing efficacy and tolerability of antidepressants compared to placebo in acute treatment at and beyond 8 weeks. DATA SOURCES: MEDLINE, Embase, PsycINFO, and CENTRAL databases were systematically searched through March 2014 using generic terms for depressive and affective disorders combined with generic terms for individual drugs and placebo...
January 3, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28068459/does-pharmacogenomic-testing-improve-clinical-outcomes-for-major-depressive-disorder-a-systematic-review-of-clinical-trials-and-cost-effectiveness-studies
#18
Joshua D Rosenblat, Yena Lee, Roger S McIntyre
OBJECTIVE: Pharmacogenomic testing has become scalable and available to the general public. Pharmacogenomics has shown promise for predicting antidepressant response and tolerability in the treatment of major depressive disorder (MDD). In theory, pharmacogenomics can improve clinical outcomes by guiding antidepressant selection and dosing. The current systematic review examines the extant literature to determine the impact of pharmacogenomic testing on clinical outcomes in MDD and assesses its cost-effectiveness...
January 3, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28064115/do-social-functioning-and-symptoms-improve-with-continuation-antidepressant-treatment-of-persistent-depressive-disorder-an-observational-study
#19
David J Hellerstein, Kallio Hunnicutt-Ferguson, Jonathan W Stewart, Patrick J McGrath, Samantha Keller, Bradley S Peterson, Ying Chen
OBJECTIVE: To determine efficacy of continued treatment with the serotonin norepinephrine reuptake inhibitor duloxetine on symptom reduction and functional improvement in outpatients with dysthymia. METHOD: Fifty outpatients with DSM-IV-TR diagnosed dysthymia who had participated in a 10 week double-blind, placebo-controlled study of duloxetine received open treatment for three months. Nineteen duloxetine responders continued duloxetine, 24 patients initially treated with placebo started open duloxetine treatment, and 7 duloxetine non-responders were treated with desvenlafaxine or bupropion, selected by clinician choice...
December 20, 2016: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28045473/gabapentin-for-fibromyalgia-pain-in-adults
#20
REVIEW
Tess E Cooper, Sheena Derry, Philip J Wiffen, R Andrew Moore
BACKGROUND: This review replaces part of an earlier review that evaluated gabapentin for both neuropathic pain and fibromyalgia, now split into separate reviews for the two conditions. This review will consider pain in fibromyalgia only.Fibromyalgia is associated with widespread pain lasting longer than three months, and is frequently associated with symptoms such as poor sleep, fatigue, depression, and reduced quality of life. Fibromyalgia is more common in women.Gabapentin is an antiepileptic drug widely licensed for treatment of neuropathic pain...
January 3, 2017: Cochrane Database of Systematic Reviews
keyword
keyword
91584
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"